270.9500 -3.90 (-1.42%)
NSE Nov 04, 2025 15:31 PM
Volume: 38,072
 

270.95
-1.42%
Prabhudas Lilladhar
1QFY21 earnings were mixed with revenue lower than our estimate but EBITDA and PAT higher due to higher gross margin and lower SG&A.; INDR's key growth driver for FY22E India formulation declined by 9% (55% of revenue) YoY even after restructuring its marketing divisions and sales team with new taxonomy of portfolio, focus and allotment of MRs (including additional headcounts). Europe has already made a strong comeback with...
Indoco Remedies Ltd. has an average target of 325.00 from 2 brokers.
More from Indoco Remedies Ltd.
Recommended